The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The use of sodium-glucose contransporter-2 (SGLT2) inhibitors may lead to serious side effects, warns the U.S. Food and Drug Administration (FDA). One such side effect is diabetic ketoacidosis, a serious condition where the body produces high levels of blood acids (ketones) that may require hospitalization.

SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.

The SGLT2 drugs involved in the warning include:

  • Farxiga – dapagliflozin (AstraZeneca)
  • Glyxambi – empagliflozin combined with linagliptin (Lilly/Boehringer)
  • Jardiance – empagliflozin (Lilly/Boehringer)
  • Invokamet – canagliflozin combined with metformin (Johnson & Johnson)
  • Invokana – canagliflozin (Johnson & Johnson)
  • Xigduo XR – dapagliflozin combined with metformin (AstraZeneca)

Dangerous Side Effects

  • Brain swelling
  • Diabetic Ketoacidosis (may appear as a severe case of the flu with nausea, confusion, coma and other symptoms)
  • Kidney failure
  • Heart attack
  • Stroke

What Patients should do

Most importantly, consult your medical doctor before discontinuing the use of any drug. A serious health emergency may arise if the medicine is suddenly stopped.

Next, Contact Us if you or a loved one has taken Invokana or any of the other SGLT2 drugs outlined above and suffered a heart attack, kidney failure, stroke or diabetic ketoacidosis. We are national defective drug attorneys at Sheller PC and we can help you determine if you have a case and if you are eligible for compensation from the manufacturers of SGLT2 drugs. Contact us today by calling 800-883-2299, or by filling out the inquiry form at the bottom of this page or chatting with us.

The drug labels do not warn of these serious side effects.

Diabetes Drugs

It is estimated that in 2013, the top ten diabetes drugs generated $28 billion in sales out of the $35 for all diabetes drugs. Moreover, by the year 2017 one estimate says the diabetes drug market will surge to $55.3 billion worldwide.

Although drugs of this nature that treat conditions such as diabetes, can save lives, there needs to be high standards of development, marketing research and testing of these drugs.

Comments are closed.

Of Interest